GrimAge Epigenetic Clocks Accurately Predict Death Risk in Large Study
Analysis of 1,942 people shows GrimAge and GrimAge2 epigenetic clocks outperform other aging biomarkers at predicting mortality.
Summary
Researchers analyzed 11 different epigenetic clocks in 1,942 adults to determine which best predicts mortality risk. Only GrimAge and GrimAge2 showed strong, linear associations with death from all causes, cancer, and heart disease over 17 years of follow-up. These DNA methylation-based biomarkers significantly outperformed other aging clocks like HorvathAge and PhenoAge. The findings validate GrimAge clocks as superior tools for assessing biological aging and mortality risk in clinical and research settings.
Detailed Summary
This comprehensive study validates which epigenetic aging biomarkers most accurately predict mortality risk, providing crucial guidance for longevity research and clinical practice.
Researchers analyzed data from 1,942 NHANES participants (median age 65) followed for up to 17 years, comparing 11 different epigenetic clocks including HorvathAge, PhenoAge, GrimAge, and the newer GrimAge2. These clocks use DNA methylation patterns to estimate biological age, with "age acceleration" measuring how much someone's biological age exceeds their chronological age.
The results were striking: only GrimAge and GrimAge2 age acceleration showed consistent, linear relationships with mortality risk. Both clocks significantly predicted all-cause mortality, cancer deaths, and cardiac deaths across most demographic subgroups. Other widely-used clocks like HorvathAge and PhenoAge showed weaker or inconsistent associations with death risk.
During follow-up, 997 participants (51%) died, including 204 cancer deaths and 262 cardiac deaths. Using sophisticated statistical modeling, researchers found that higher GrimAge acceleration consistently predicted increased mortality risk, while other clocks showed variable or non-linear patterns that limited their predictive value.
These findings have important implications for longevity research and clinical practice. GrimAge clocks could help identify individuals at higher risk for premature death, guide preventive interventions, and serve as biomarkers in anti-aging research. The study's large sample size and long follow-up period strengthen confidence in these results, though the analysis was limited to older adults and may not apply to younger populations.
Key Findings
- Only GrimAge and GrimAge2 clocks showed linear associations with mortality risk
- Both clocks predicted all-cause, cancer, and cardiac death equally well
- Other popular aging clocks like HorvathAge showed weaker mortality prediction
- Results were consistent across most demographic and health subgroups
- GrimAge clocks outperformed alternatives in statistical model comparisons
Methodology
Retrospective cohort study of 1,942 NHANES participants followed for median 208 months. Used restricted cubic spline models and Cox regression to assess mortality associations, comparing 11 epigenetic clocks.
Study Limitations
Study limited to older adults (median age 65), potentially limiting generalizability to younger populations. Observational design cannot establish causation between epigenetic age acceleration and mortality.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.